Previous 10 | Next 10 |
Sprint (NYSE: S ) +74% after judge approves T-Mobile merger . More news on: Sprint Corporation, Rexahn Pharmaceuticals, Inc., ZK International Group Co., Ltd., Stocks on the move, Read more ...
HOUSTON , Feb. 11, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indic...
Source (Shutterstock/Liya Graphics) Introduction Gilead Sciences ( GILD ) was positioned to be the poster child of Trump's plan to eradicate HIV, as outlined in my previous article . Like almost all outbreaks including the Wuhan coronavirus, the only effective way to complete...
The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...
Company Overview Marker Therapeutics ( MRKR ) was formed in October 2017 with a merger of privately held company Marker Cell Therapy, Inc. and TapImmune. Marker is a clinical-stage biotechnology company specializing in the development and commercialization of novel cell-based immunothera...
Gainers: Nortech Systems (NASDAQ: NSYS ) +98% . More news on: Nortech Systems Incorporated, FuelCell Energy, Inc., Cardlytics, Inc., Stocks on the move, Read more ...
Image source: The Motley Fool. Marker Therapeutics, Inc. (NASDAQ: MRKR) Q3 2019 Earnings Call Nov 12, 2019 , 5:00 p.m. ET Operator Continue reading
Thinly traded micro cap Marker Therapeutics (NASDAQ: MRKR ) is down 16% premarket on light volume in apparent reaction to its disclosure that its Phase 2 clinical trial, Marker AML, evaluating its MultiTAA T-cell therapy in post-allogeneic hematopoietic stem cell transplan...
Marker Therapeutics, Inc. (MRKR) Q3 2019 Earnings Conference Call November 12, 2019 5:00 PM ET Company Participants Tony Kim – Chief Financial Officer Peter Hoang – President and Chief Executive Officer Mythili Koneru – Senior Vice President-Clinical Developm...
Gainers: CDLX +20.8% . TWOU +14.6% . DDOG +14.2% . VRAY +9.3% . NBRV +8.4% . More news on: Cardlytics, Inc., 2U, Inc., Datadog, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...